Cabizitaxel, a novel drug for castration-resistant prostate cancer

Failure of the first-line drug docetaxel to the treatment of castration-resistant prostate cancer (CRPC) remains a challenge. Cabazitaxel, a novel semisynthetized taxane, shows a broad antitumor activity against tumors that are sensitive or insensitive to docetaxel. Phase III clinical trial revealed that cabazitaxel significantly improves the PSA and tumor response rate of CRPC, and prolongs the time to disease progression and overall survival time. The most common side effect is hematological toxicity and the most common nonhematological side effect is diarrhea.